Management Forum Logo

Presented by
Management Forum

Drafting Effective Pharmaceutical Patents Training Course

Drafting successful pharmaceutical patents is complex and there are many pitfalls and risks to be aware of. You need to ensure you’re maximising the protection for your, and your client’s, pharmaceutical inventions thorough both primary and secondary pharmaceutical patents.

12-15 May 2025
+ 3-6 November 2025 »
from £1199

Need help? Enrol/reserve

Format: Live online
CPD: 12 hours for your records
Certificate of completion

Enrol/reserve Download Print Share Email

Course overview

The area of pharmaceutical patents is highly complex with many pitfalls to be aware of and to know how to mitigate against. During this course the expert faculty will take you through the key differences between the European and US systems and how these can impact your patents. They will explore the latest strategies and give you useful insights and practical solutions to your drafting issues. By understanding the importance of aligning your patent and regulatory strategies, you will improve your pharmaceutical claim drafting skills to the best advantage.

The practical claim drafting exercises included in the course will give you an opportunity to get to grips with the information in a safe environment and under the guidance of the expert trainers. They will help embed what you have learnt so that it can be taken back to the workplace and put into practice.

As well as receiving inside knowledge and top tips and advice from the highly experienced speaker, the course also provides a valuable opportunity to network with others in similar roles from different companies. By attending, you can discuss your challenges with colleagues and our expert faculty and find solutions to your questions.

Key topics covered in this intensive training programme include:

Drafting primary patents and secondary patents
Key differences between drafting for Europe versus the US
Claim drafting strategies for antibodies and other biologics
Drafting claims that ‘follow the label’
Drafting patent applications with sufficient supporting data – how much is enough?
Aligning your patent strategy with regulatory issues

This course is part of our collection of IP & Patents Training Courses.

Benefits of attending

By attending this course you will:

Understand how to draft primary patents in the small molecule and biologics fields
Ensure comprehensive protection for innovations from genetic sequences through to therapeutic applications
Learn how to protect medical use claims – first, second and Swiss-type
Get to grips with drafting claims for infringement
Consider regulatory issues and data protection
Enhance your knowledge of the data needed to support patent applications
Recognise the importance of correct data in avoiding inequitable conduct
Boost your knowledge of secondary patents and their benefits

Who should attend?

This course has been specially designed for:

Patent attorneys
In-house lawyers
Private practice lawyers
Patent agents and consultants

Enrol/reserve

This course will cover:

Introductory summary of the course

Overview of the programme
Patentability basics

Drafting primary patents – small molecules

Protecting pharmaceutical compositions
Protecting methods of treatment
Protecting medical use claims (first, second and Swiss-type)

Drafting primary patents – biologics

Drafting sequence disclosures
Protecting antibodies, stem cells and microorganisms
Drafting generic and species claims
Drafting functional claim language
Protecting gene therapy inventions

Primary patents workshop

Selection inventions
Drafting claims for infringement
- Distilling down the invention disclosure
- Patenting later developments
Practical examples and drafting exercises

Drafting with a focus towards interplay with regulatory issues

Patent term extension and SPCs
Regulatory issues and data protection – drafting to ‘follow the label’
The ANDA litigation process and enforcement of listed patents
Overlay of patent protection with FDA exclusivity – the FDA Orange Book
Strategies for protecting biologics

Data needed to support patent applications

What data must be included?
When must the data be included?
Consideration of post-filing date data
US written description
The importance of correct data – avoiding inequitable conduct

Secondary patents

Protecting dosage regimes, modes of administration, patient groups
Protecting polymorphs (crystals, enantiomers, salts)
Protecting metabolites
Protecting new formulations
Protecting process patents
Protecting methods of diagnosis and surgery

Secondary patents workshop

Establishing patentability: inventive step vs non-obviousness
Strategies for using post-filing evidence
Practical examples and drafting exercises

Enrol/reserve

Amanda Murphy
Finnegan

Dr. Amanda Murphy is a Partner in Finnegan’s Washington, DC Office and focuses her practice on strategic client counseling, portfolio management, and patent prosecution for a range of clients, including small startup companies, research foundations, and large biotechnology and pharmaceutical companies.
Amanda provides patentability opinions, prepares new patent applications, prosecutes U.S. and foreign applications, and represents appellants before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She has experience in prosecuting inter partes and ex parte reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe. In addition to her patent counseling and prosecution practice, Amanda also routinely represents petitioners and patent owners in inter partes review (IPR) and post grant review (PGR) proceedings before the PTAB. As part of that practice, Amanda works with experts to develop technical and legal bases for challenging or defending issued patents, and manages the preparation of substantive written submissions. She also provides strategic advice and pre-litigation analysis and prepares freedom-to-operate, enforceability, and infringement opinions.

More details

NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:

30% off the 2nd delegate*
40% off the 3rd delegate*
50% off the 4th delegate*

Please contact us for pricing if you are interested in booking 5 or more delegates

12-15 May 2025

Live online

13:30-17:00 UK (London) (UTC+01)
14:30-18:00 Paris (UTC+02)
08:30-12:00 New York (UTC-04)
Course code 14681

GBP 1,199 1,399
EUR 1,679 1,959
USD 1,927 2,239

Until 07 Apr

4 sessions of live online training
Browser-based, no download usually required
See presenters and interact with fellow attendees
Download documentation and certification of completion
Fair transfer and cancellation policy

View basket

Not ready to book yet?

for 7 days, no obligation

3-6 November 2025

Live online

13:30-17:00 UK (London) (UTC+00)
14:30-18:00 Paris (UTC+01)
08:30-12:00 New York (UTC-05)
Course code 15029

GBP 1,199 1,399
EUR 1,679 1,959
USD 1,927 2,239

Until 29 Sep

4 sessions of live online training
Browser-based, no download usually required
See presenters and interact with fellow attendees
Download documentation and certification of completion
Fair transfer and cancellation policy

View basket

Not ready to book yet?

for 7 days, no obligation

* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price; and apply only when booking multiple delegates on the same date.

Reviews of IPI's Drafting Effective Pharmaceutical Patents training course

A very good webinar overall and felt very worthwhile. I am really glad that I attended. After the first day the sessions were livelier, and the polls added a little extra dimension to recap and tease out some of the points made in the presentations. The discussion between the EU and US based presenters on points of divergence worked really well and made the sessions less static and more engaging.

Nov 1 2022

Angela King United Kingdom
Patent Attorney, Croda Europe Limited